Search the Newsreel

Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance

Beta Bionics reported net sales of $32.0 million for the second quarter of 2026, marking a 38% increase year-over-year, with strong growth in its Pharmacy Benefit Plan channel. The company initiated a pivotal trial for its iLet device in type 2 diabetes and updated …

Archer Aviation (ACHR) Joins Electric Skyways Push, Is The Stock Trading At A Discount?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Archer Aviation (ACHR) is back in focus after joining BETA Technologies and Macquarie Capital to launch America's Consortium for Electric Skyways, a multi partner …

Beta Bionics, Inc. (BBNX) Reports Q2 Loss, Tops Revenue Estimates

Beta Bionics, Inc. (BBNX) reported a Q2 loss of $0.53 per share, exceeding the Zacks Consensus Estimate of a $0.62 loss, and revenues of $32.01 million, surpassing estimates by 2.07%. Despite outperforming earnings and revenue expectations, the company's shares have declined by 48.2% year-to-date, …

Here's Why We're Not Too Worried About Beta Bionics' (NASDAQ:BBNX) Cash Burn Situation

Beta Bionics (NASDAQ:BBNX) has a solid cash runway of about 3.3 years, holding US$200 million in cash against an annual burn of US$61 million. Despite a slight increase in cash burn, the company's strong revenue growth of 58% and low cash burn relative to …

UBS Adjusts Price Target on Beta Bionics to $22 From $24, Maintains Buy Rating

UBS has adjusted its price target for Beta Bionics (BBNX) to $22, down from $24, while maintaining a Buy rating on the stock. This update reflects a revised valuation perspective for the medical device company, which specializes in insulin delivery systems for people with …

Earnings To Watch: Beta Bionics Inc (BBNX) Reports Q2 2026 Result

Beta Drugs Q1FY27 net profit rises 41% to ₹165 Mn on strong sales

Beta Bionics Inc (BBNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Beta Bionics Inc (BBNX) based on business segments for FY2025. The company's revenue streams are primarily from DME channel sales of iLet and single-use products, and PBP channel sales of single-use products and iLet. The data …

Free cash flow of BETA Technologies, Inc. Class A – DUS:9N8

This article provides financial information specifically the free cash flow for BETA Technologies, Inc. Class A (DUS:9N8). It highlights that the market was closed with no trades recorded at the time of publication and lists metadata providers for the financial data presented.

Beta Bionics (BBNX) Stock Fair Value Falls As Medtech Reset Tempers iLet And Mint Optimism

The fair value estimate for Beta Bionics (BBNX) has decreased from US$31.30 to US$19.80 per share, aligning more closely with current analyst price targets. This adjustment reflects a balance between continued optimism for their iLet product and planned Mint launch, and broader medtech sector …

BETA Technologies, Inc. Class A Revenue Breakdown – DUS:9N8

BETA Technologies, Inc. (DUS:9N8) generated €30.32 million in revenue last year, primarily from its Electric Aircraft Service segment, which contributed €19.74 million. The United States was the largest geographical contributor, accounting for the entire €30.32 million revenue. This highlights a significant increase from €12.78 …

Beta Bionics Inc (BBNX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on Beta Bionics Inc (BBNX) stock, focusing on its dividend and stock split history. It indicates that the company has distributed $0.00 in dividends over the past five years, with no dividend data currently available. The page also presents current …

Beta Bionics Inc (BBNX) Institutional Confidence

Beta Bionics Inc (BBNX) has an institutional shareholding score of 10.00, ranking it 1st in the Healthcare Equipment & Supplies industry. Institutional shareholding proportion increased by 4.12% quarter-over-quarter to 110.51%. Frank Sands is the largest institutional shareholder, holding 3.08 million shares, representing 8.01% of …

Beta Bionics (BBNX) sees 6.9% stake reported by Divisadero Street group

A Schedule 13G SEC filing reveals that Divisadero Street Capital Management, LP, along with William Zolezzi and related entities, has acquired a significant beneficial ownership of 3,072,985 shares in Beta Bionics, Inc. (BBNX), representing 6.9% of the common stock. This filing indicates shared voting …

BBNX|Beta Bionics Inc|Price:16.330|Chg%:+0.200

Beta Bionics Inc. (BBNX) is a commercial-stage medical device company focused on solutions for insulin-requiring diabetes patients, particularly with its iLet Bionic Pancreas. The company exhibits strong fundamentals with significant revenue growth and high institutional ownership, though its stock performance has been mixed recently. …

BETA Technologies (NYSE: BETA) sees Security Control Agreement terminated

BETA Technologies, Inc. (NYSE: BETA) announced the termination of its Security Control Agreement, effective July 14, 2026. This agreement, established with QIA Industrials Holding, LLC and the U.S. Department of Defense, aimed to mitigate foreign ownership concerns. The Defense Counterintelligence and Security Agency deemed …

BETA ENERJI VE T - KAP Haberleri - 2026-07-23 tarihli

Beta Technologies CEO Clark Kyle disposes of 5,000 common shares worth $87,592

Beta Technologies President and CEO Kyle Clark sold 5,000 Class A common shares on July 16, 2026, at a weighted-average price of $17.52, totaling $87,592. Following this transaction, Godric's Hollow Trust indirectly holds 5,489,837 Class A shares. The information for this brief was generated …

Operating margin % of BETA Technologies, Inc. Class A – DUS:9N8

The article displays the operating margin percentage for BETA Technologies, Inc. Class A, traded on the Dusseldorf Stock Exchange under the symbol DUS:9N8. It is a financial data point presented within the context of the company's financial overview on the TradingView platform.

Beta Enerji’den (BETAE) 13,5 milyon TL’lik ihale başarısı

Beta Drugs Reports Q1 Consolidated Net Profit of 158M Rupees, Revenue at 1.27B Rupees

BETA Technologies (BETA) Lands Loganair Deal For Europe’s First Electric Airline Fleet

BETA Technologies has signed a deal with Loganair for its all-electric ALIA CTOL aircraft, positioning Loganair to become Europe's first airline to operate an electric fleet. This agreement validates BETA's technology with an established carrier and highlights the potential for electric aviation in regional …

BETA Technologies, Inc. (BETA) CEO sells 5,000 shares in 10b5-1 trade

BETA Technologies, Inc.'s CEO, Clark Kyle, through The Godric's Hollow Trust, sold 5,000 shares of Class A common stock on July 16, 2026, at a weighted average price of $17.5183 per share. This transaction was conducted under a pre-established 10b5-1 trading plan. Following the …

BETA Technologies (BETA) Joins Electric Skyways Consortium, Is It Still 38% Below Fair Value?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. BETA Technologies (BETA) is back in focus after joining Archer Aviation and Macquarie Capital to form America's Consortium for Electric Skyways, a plan to deploy …

Beta Drugs consolidated net profit rises 35.04% in the June 2026 quarter

Beta Bionics (BBNX) price target decreased by 11.15% to 20.99

This article reports that Beta Bionics (BBNX) has experienced an 11.15% decrease in its price target, bringing it down to $20.99. No further details are provided regarding the reasons behind this adjustment or the analyst responsible. The content is very brief and lacks additional …

BETA Technologies sets 8:30 a.m. webcast for Aug. 12 results

BETA Technologies (NYSE: BETA) will release its second-quarter 2026 financial and operating results before the market opens on August 12, 2026. The company will also host a live webcast at 8:30 a.m. ET to discuss these results. BETA Technologies specializes in designing, manufacturing, and …

Beta Technologies CEO Clark sells $810,337 in company stock By Investing.com

BETA Technologies CEO Kyle Clark sold $810,337 worth of Class A common stock through The Godric’s Hollow Trust in mid-July. This sale, part of a pre-established trading plan, occurred as the stock trades at $18.53, down 48% over the past year. Despite strong revenue …

BETA Technologies (BETA) trust 10b5-1 sale of 45K Class A shares

Clark Kyle, a director and officer of BETA Technologies, reported the indirect sale of 45,000 Class A shares by The Godric's Hollow Trust between July 13-15, 2026. These sales, executed under a 10b5-1 plan, were at weighted-average prices ranging from $17.48 to $18.42 per …

BBNX Maintained by Goldman Sachs -- Price Target Raised to $19.0

Goldman Sachs has maintained its 'Buy' rating for Beta Bionics (BBNX) and raised the price target to $19.00 from $17.00, reflecting optimism about the company's growth, particularly its iLet Bionic Pancreas product. Despite this positive analyst outlook, BBNX has a low GF Score™ of …

Is BETA Technologies, Inc. (BETA) A Good Stock To Buy Now?

Beta Enerji halka arz sonuçları açıklandı mı? Beta Enerji BETAE kişi başına düşecek lot miktarı

TSK Beta Enerji izahname bilgisi paylaştı

Beta Enerji halka arzı hakkında bilmen gereken her şey! – 2026

Beta Drugs completes Nivian Lifesciences acquisition

Earnings Troubles May Signal Larger Issues for Beta Drugs (NSE:BETA) Shareholders